The biomarker results from these negative assays demonstrated subsets of patients that were more sensitive to anti-PD-1, including those with high PD-L1 expression, unstable microsatellite tumours, and tumours with a high tumour mutation load. The gene discussed is CD274; the disease is neoplasm.